Korean Market
FTC
HK inno.N
★

HK inno.N Announces Routine Annual Corporate Group Status Disclosure, No Material Changes

 
EXCH
HK inno.N
★

Decision on 97 Billion KRW New Production Facility Investment

 
EXCH
HK inno.N
★★

1Q 2026 Preliminary: Operating Profit 33.2B KRW, +30.8% YoY

 
EXCH
HK inno.N
★

2026 Q1 Earnings Conference Call IR Held

 
EXCH
HK inno.N
★

NDR for Institutional Investors on April 29-30, 2026 (Sponsored by Yuanta Securities)

 
PERI
HK inno.N
★★

HK inno.N Q1 2026: Revenue KRW 258.7B, OP KRW 33.2B, R&D Pipeline Advancing

 
EXCH
HK inno.N
★

IN-115314 Atopic Dermatitis Treatment Gets FDA Phase 1b IND Approval